PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20841518-1 2010 OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus. mitiglinide 81-92 insulin Homo sapiens 109-116 26336611-14 2015 Additional therapy to sitagliptin or mitiglinide is clearly required to obtain equivalent glycemic control in patients using a higher dose of insulin. mitiglinide 37-48 insulin Homo sapiens 142-149 10509738-5 1999 These findings suggest a much higher affinity of glibenclamide than S21403 for the artificial phospholipid bilayer, this coinciding with a higher biological potency, as insulin secretagogue, of the hypoglycemic sulfonylurea as compared to meglitinide analog. mitiglinide 68-74 insulin Homo sapiens 169-176 31884929-4 2020 Over the past half century, these drugs, together with the subsequent non-sulfonylureas (glinides), have been the main oral drugs for insulin secretion. mitiglinide 89-97 insulin Homo sapiens 134-141 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. mitiglinide 26-34 insulin Homo sapiens 70-77 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. mitiglinide 26-34 insulin Homo sapiens 192-199 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. mitiglinide 26-34 insulin Homo sapiens 192-199 17185877-0 2007 Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. mitiglinide 45-56 insulin Homo sapiens 147-154 16543674-1 2006 Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes. mitiglinide 0-11 insulin Homo sapiens 43-50 16543674-2 2006 While mitiglinide enhances postprandial requirement of insulin, the efficacy of mitiglinide combined with insulin has yet to be established. mitiglinide 6-17 insulin Homo sapiens 55-62 16543674-3 2006 We investigated the efficacy of mitiglinide combined with insulin glargine, the first soluble insulin analog that has a flat and prolonged effect. mitiglinide 32-43 insulin Homo sapiens 94-101 15467258-2 2004 Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia. mitiglinide 0-11 insulin Homo sapiens 36-43 15467258-2 2004 Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia. mitiglinide 0-11 insulin Homo sapiens 146-153 30621663-8 2019 After several therapeutic trials, cessation of exogenous insulin and addition of mitiglinide to liraglutide with voglibose finally attenuated glycemic fluctuations with increased postprandial insulin secretion. mitiglinide 81-92 insulin Homo sapiens 192-199 24215809-18 2013 CONCLUSIONS: Mitiglinide improved postprandial insulin secretion pattern and thereby suppressed postprandial glucose spike. mitiglinide 13-24 insulin Homo sapiens 47-54 25560470-1 2015 Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. mitiglinide 49-60 insulin Homo sapiens 142-149 25810423-0 2015 Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin. mitiglinide 22-33 insulin Homo sapiens 146-153 25810423-10 2015 Hence, we have demonstrated the efficacy and safety of the add-on treatment with mitiglinide in type 2 diabetic patients, receiving the combination therapy of sitagliptin and insulin glargine. mitiglinide 81-92 insulin Homo sapiens 175-182 25560470-1 2015 Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. mitiglinide 49-60 insulin Homo sapiens 84-91 22994875-8 2012 Mitiglinide and the combination restored early insulin response, whereas the combination provided an insulin-sparing effect compared with mitiglinide alone. mitiglinide 0-11 insulin Homo sapiens 47-54 23797928-0 2013 Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus. mitiglinide 11-22 insulin Homo sapiens 39-46 23992284-1 2013 INTRODUCTION: Mitiglinide , a rapid-acting insulin secretion-stimulating agent, is approved in Japan for the treatment of type 2 diabetes (T2DM). mitiglinide 14-25 insulin Homo sapiens 43-50